Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JW1103
- Development stage
- Preclinical
- Lead developer
- JW Pharmaceutical
- Modality
- Small Molecules
01
Overview
JW1103 is a preclinical small molecule Wnt pathway activator being developed by JW Pharmaceutical. It is designed to stimulate the Wnt/β-catenin signaling pathway, which plays a critical role in bone formation and tissue regeneration. The drug is primarily targeted at rare diseases, specifically osteogenesis imperfecta (brittle bone disease), where it aims to increase bone mineral density and strength by promoting the differentiation and activity of osteoblasts. JW1103 is part of JW Pharmaceutical's proprietary library of Wnt modulators and is being investigated for its potential to treat conditions characterized by bone loss or impaired regeneration.
Beyond the preview
Go deeper on JW1103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JW1103.